Background: Fibroblast growth factors (FGF) and their receptors are complex intracellular pathway that controls cellular proliferation and tumour growth and invasion. FGFR alterations have been shown to be associated with the initiation and progression of gastric cancer (GC). We investigated the correlations of the FGFR2 amplification and expression with clinicopathological characteristics and outcomes in advanced/ metastatic gastric cancer patients who received systemic chemotherapy based on fluoropyrimidine. Methods: FFPE tumor samples were obtained from patients with advanced/ metastatic gastric cancer who received systemic chemotherapy based on fluoropyrimidine diagnosed at 2 cancer centers between 2010 and 2016. FGFR2 gene copy number was assessed by FISH method using probes specific for the 10q26 locus and the chromosome 10 centromere (CEN10). FGFR2 amplification was defined as FGFR2/CEN10 2.0. FGFR2 protein expression was determined by immunohistochemistry. Overexpression was defined as complete membrane staining intensity 2 þ (graded from 0 to 3þ) in cancer cells. Results: From the cohort consists of 186 GC patients, FFPEs were available from 123 pts. FGFR2 amplification was found in 4/123 (3,3%) patients with FGFR2/CEN10 median 1,16 þ1,77 and range 0,8-20,0. FGFR2 overexpression was observed in 5/123 (4,1%) patients. FGFR2 amplification had no significantly impact on overall survival (OS) and progression free survival (PFS) in compare those without FGFR2 amplification (respectively, HR ¼ 1.43, 95% CI 0.54 to 4.04, p ¼ 0.4426 and HR ¼ 3.06, 95%CI 0.94 to 9.97, p ¼ 0.0628). There was no prognostic significance observed for FGFR2 overexpression on OS and PFS (respectively, HR ¼ 1.27, 95%CI 0.52 to 3.15, p ¼ 0.5961 and HR ¼ 2.44, 95%CI 0.88 to 6.78, p ¼ 0.0863). Conclusions: The rate of GC patients with tumors positive for FGFR2 amplification or expression was consistent with the data published in the literature. However FGFR2 amplification and overexpression has no prognostic significance in advanced/ metastatic gastric cancer patients who received systemic chemotherapy based on fluoropyrimidine. Therefore, further investigation on a larger population is required. Legal entity responsible for the study: Celon Pharma. Background: Stomach cancer (SC) is one of the most common cancers and the third leading cause of cancer-related deaths; however, it is often diagnosed at later stages. Literature data on epigenetic changes in stomach cancer and precancer, in particular on hypermethylation of tumor suppressor genes, indicate its important role in gastric tissue malignization. Methods: Bisulfite pyrosequencing was used to study the CpG methylation in promoter sites of 6 tumor suppressor genes (APC, CDH13, MLH1, MGMT, P16 and RASSF1A). The study included paired bioptates of tumors and intact tissues obtained from 35 patients (25 men, 10 women, median age 67 years) with stomach cancer (G2-3 adenocarcinoma, T3-4N0-2M0). Results: The rates of hypermethylation of the MGMT, P16 and RASSF1A genes amounted to 23%, 14% and 11% respectively. Increased methylation in the promoter site of the MLH1 gene was observed in one case only (11% vs 4%). Regulatory sites of CDH13 and APC genes in intact tissues were atypically hypermethylated in 80% of cases, which was obviously associated with functional characteristics of the gastric mucosa. However, the methylation of the promoter site of the CDH13 gene in nontumor tissue was 2 times lower compared to the local tumor (p ¼ 0.002) and 1.5 times lower compared to the tumor with lymph node metastases (p ¼ 0.012). An association
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Conclusions:
We observed hypermethylation of the promoter sites of the MGMT, P16 (CDKN2A) and RASSF1A genes in malignant stomach tissues compared to intact tissues which demonstrated the importance of disorders of repair processes (MGMT and RASSF1A) and mechanisms of regulation of the cell cycle (CDKN2A) in the malignization of stomach tissues. The methylation status of these genes can be a useful biomarker for early diagnosis of stomach cancer or possible therapeutic targets. Background: Gastric cancer (GC) is a leading cause of cancer deaths. Tumor staging has been conceived as the best predictor of patient survival. Nevertheless, TNM classification has limited power to fully reflect the complicated progression events. Prognosis varies from individual to individual even though the two patients stay in a similar tumor stage, therefore the molecular biology of the individual tumor might be the key point to better understand the nature of GC. The identification of somatic mutations (SM) has the potential to offer diagnostic and prognostic information. The present study is focusing on implementation of clinical exome sequencing for SM identification. Methods: 18 gastric cancer specimens and 18 corresponding adjacent normal gastric specimens were obtained from GC patients with stages from Ia to IV. Paired-ended sequencing was performed using Trusight one sequencing panel (Illumina) on a NEXTSEQ500 platform. 94,5% of the target regions were represented with an average sequencing depth of 20-fold. A somatic variant list was generated for each patient by using MuTect. Results: Tumor and normal library targeted 4,813 genes associated with known clinical phenotypes were sequenced with mean coverage of 99x. Mean number of detected variations was 7613 per sample. After MuTect filtration the amount of SM was varied from 2 to 414 per sample. We found 692 SM: 5 pathogenic mutations in TP53, ARID1A and HER2 genes, 40 were described in COSMIC and dbSNP database, the rest were novel mutations. By the time of 2 years follow-up, 5 patients (27.8%) died, all of them had intermediate grade adenocarcinoma. Importantly, all of them had dramatic number of SM (from 37 to 414). At the operation moment 3 of them had III stage, 2 of them had 1b and IIa stages. For patients with overall survival (OS) > 2 years the number of SM increases with disease stage: I-II stage from 2 to 12, III stage -from 2 to 20, IV stagefrom 12 to 43. For patients with OS < 2 years the number of SM was high nevertheless stage. Conclusions: We found more than 600 novel mutations, from them 18 mutations were localized in genes previously associated with gastric cancer pathogenesis. In the current moment of the investigation patients with high level of SM have unfavorable prognosis (OS less than 2 year) regardless of stage. Background: Histone methyltransferase G9a is up-regulated in a wide variety of human tumors. The aims of this study are to clarify G9a expression in tumor tissues and its adjacent normal tissues of gastric cancer, to investigate the effect of G9a on tumor invasion and metastasis of gastric cancer by up-regulating and down-regulating the expression of G9a in gastric cancer cells, and to validate it in animal model. 
